Theorem Clinical Research and Excel Life Sciences have formed a strategic relationship.
Theorem Clinical Researchand Excel Life Sciences (ELS) have formed a strategic relationship to bolster Theorem’s clinical development offerings in India, including local site management expertise. ELS has long-standing relationships with more than 1,000 hospitals and research centers across 25 cities throughout India, covering a broad range of therapeutic disciplines.
“ELS complements our own strategic offerings in the region and around the globe and extends our clinical trial capabilities,” said Marc Hoffman, M.D., Theorem senior vice president and general manager of biopharmaceutical development. “Collaborating together we can offer sponsor companies access to a wealth of high-quality research centers in India, a well-established research team with a strong understanding of ICH-GCP and, most importantly, the local knowledge for successful conduct of studies in country. There are obvious benefits for all: for sponsors, more robust patient recruitment and retention and, for patients, access to cutting-edge therapies and research programs.”
ELS has developed one of the largest networks of investigators and investigative sites within India.
“Site management services from Excel Life Sciences help take the burden off investigators so they can focus on patient care and ensure that the study is conducted to the highest standards for quality, ethics and performance,” said Vijai Kumar, M.D., president and chief medical officer of ELS. “This support ensures collection of high-quality study data necessary for the U.S. Food and Drug Administration, the European Medicines Agency and other global regulatory and product approval agencies. Operationally, our site management focus has translated into India patient enrollment and retention numbers that are significantly higher than comparative global performance for the same study.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.